The findings and conclusions in these presentations have not been formally disseminated by the Centers for Disease Control and Prevention and should not be construed to represent any agency determination or policy.

Tuesday, May 9, 2006 - 11:00 AM
33

Adolescent chlamydia and gonorrhea screening practices; findings from a survey of New York City health-care providers

Meighan E. Rogers1, Kelly Morrison Opdyke2, Susan Blank3, and Julia A. Schillinger3. (1) Bureau of STD Control, New York City Department of Health and Mental Hygiene, 125 Worth Street CN #73, Room 207, New York, NY, USA, (2) Cicatelli Associates Inc, 505 Eighth Avenue, Sixteenth Floor, New York, NY, USA, (3) Bureau of Sexually Transmitted Disease Control, NYC DOHMH / Division of STD Prevention, CDC, 125 Worth St., Room 207, CN-73, New York, NY, USA


Background:
Annual chlamydia/gonorrhea screening is recommended for young sexually active women. One recent Colorado survey found 54% of providers reported screening adolescent females regularly for chlamydia.

Objective:
To assess frequency and predictors of New York City (NYC) provider screening for chlamydia/gonorrhea among sexually active female adolescents.

Method:
In November 2004 we mailed surveys to a random sample of 2,000 NYC providers, including physicians (MDs/DOs), nurse practitioners, (NPs) and physician assistants (PAs), obtained from a proprietary database. Survey questions ascertained frequency of provider chlamydia and gonorrhea screening. Response categories were dichotomized into “at least annual” screening and “less than annual” screening.

Result:
We obtained responses from 42% (695/1647 successfully delivered surveys). After limiting analyses to providers who reported treating adolescent females, results were available for 425 providers (295 MD/DOs; 59NP; 71PAs).. Annual chlamydia screening was reported by 54.1% (230/425); annual gonorrhea screening by 52.9% (225/425), and did not vary by provider type. Multivariate analyses indicated similar predictors for chlamydia and gonorrhea screening: female provider sex (chlamydia, OR=2.8, p<0.0005; Gonorrhea, OR=2.3, p<.005); having diagnosed a case of chlamydia or gonorrhea in the past year (chlamydia, OR=4.7, p=0.0001; gonorrhea, OR=4.9, p=0.0001); and patient load of <50 patients/week (chlamydia, OR=2.2, p<.01; gonorrhea OR=2.0, p=.01). OB/GYNS were more likely than internists to conduct annual chlamydia screening (OR=6.0, p<0.0005). OB/GYNS were also more likely than internists to conduct annual gonorrhea screening (OR=8.1, p<0.0001), as were family practitioners (OR=3.1, p<0.05), and pediatricians (OR=2.3, p<0.05).

Conclusion:
The proportion of NYC providers that report screening female adolescents annually for chlamydia and gonorrhea is consistent with findings from previous provider surveys. Female providers and OB/GYNS were most likely to screen. Results might be biased by low response rates

Implications:
Provider adherence to screening recommendations can be improved by using the NYC Prevention Training Center to educate specialty groups through hospital grand rounds and local professional organizations..